SciSparc Ltd. SPRCa specialty clinical-stage pharmaceutical company focused on developing therapies to treat diseases of the central nervous system announced as part of the ongoing collaboration with Clearmind Medicine Inc. CMND CMND, CWYa biotech company focused on the discovery and development of novel psychedelics-derived therapeutics to solve severe undertreated mental health problems, an additional provisional patent application has been filed by Clearmind at the United States Patent and Trademark Office.

The most recent patent application relates to the protection of the unique combination of MEAI and SciSparc’s PAlmitoylethanolamide to treat depression.

As part of this collaboration, three additional patent applications were filed by Clearmind with the United States Patent and Trademark Office for the combination of SciSparc’s palmitoylethanolamide with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorders, cocaine addiction and the treatment of obesity and associated metabolic disorders. A further six patent applications have been filed for the combination of SciSparc’s PEA and lysergic acid diethylamide (LSD), psilocybin and N,N-dimethyltryptamine (DMT), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine and ketamine.

Photo of Scott Graham At Unsplash

Similar news

SciSparc completes production of its dronabinol-based drug candidate for its Tourette Syndrome clinical trial

SciSparc’s CBD-Based Drug One Step Closer To Clinical Trial In Children With Autism Spectrum Disorder

Jeffs’ Brands is acquiring a 49% stake in a company that owns a top selling brand on Amazon for $2.5 million